<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608695</url>
  </required_header>
  <id_info>
    <org_study_id>HU02</org_study_id>
    <nct_id>NCT04608695</nct_id>
  </id_info>
  <brief_title>Ovarian Needle Puncture for Follicle Activation in IVF Patients With Diminished Ovarian Reserve</brief_title>
  <official_title>Ovarian Needle Puncture for Follicle Activation in IVF Patients With Diminished Ovarian Reserve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hacettepe University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hacettepe University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Premature ovarian insufficiency (POI), is cessation of ovarian function characterized by&#xD;
      hypergonadotropic amenorrhea and hypoestrogenic syndrome before 40 years of age. About 1% of&#xD;
      women younger than 40 years old and 0.1% before 30 are affected. POI imposes a great&#xD;
      challenge on women's reproductive and long-term health, such as infertility, amenorrhea,&#xD;
      osteoporosis, and cardiovascular disease. Most patients already had impaired or complete loss&#xD;
      of fecundity when diagnosed. Currently, no optimal regimen exists to ameliorate ovarian&#xD;
      function. Typically, they end up with egg donation or adoption as an alternative way. Less&#xD;
      severe form of POI is diminished ovarian reserve (DOR). Although lack of consensus according&#xD;
      to Bologna criteria cut off for DOR was defined as (antral follicle count (AFC) &lt;5-7&#xD;
      follicles or anti-Mullerian hormone (AMH) &lt;0.5-1.1 ng/ml).&#xD;
&#xD;
      Previously it has been showed that 24% of women with POI had resumption of ovarian function&#xD;
      and 4% resulted in baby births. These data indicates residual follicles are available in&#xD;
      atrophic ovaries and have potential for development and even fertilization. In routine IVF&#xD;
      practice 15% percent of patients have poor ovarian response to ovarian stimulation. Patients&#xD;
      with DOR with a previous poor ovarian response (cycles cancelled or yielding ≤3 oocytes with&#xD;
      a conventional protocol) might have benefit from the strategies increasing follicle&#xD;
      activation and number of growing follicles and oocyte retrieved. Therefore, strategies&#xD;
      enabling ovarian resumption predictable and follicle activation feasible are promising for&#xD;
      POI/DOR treatment. Recently, In vitro Activation (IVA) approach has been proposed and live&#xD;
      births have been achieved in patients with POI. Phosphatase and tensin homolog (PTEN) enzyme&#xD;
      inhibitors and phosphatidylinositol-3 kinase activators could activate AKT pathway and&#xD;
      activate the dormant follicles. Ovarian fragmentation could lead to ovarian primary follicle&#xD;
      growth by interfering with Hippo signaling pathway. Residual follicles in patients with POI&#xD;
      could be activated to develop for egg retrieval by combination of mechanical and chemical&#xD;
      stimulation.&#xD;
&#xD;
      In 2019, Zhang et al retrospectively analyzed the follicle development and pregnancy outcome&#xD;
      in 80 POI patients after laparoscopic ovarian biopsy/scratch without using chemical agents as&#xD;
      was the case in IVA. 11 (13.75%) patients presented with ovarian function resumption, three&#xD;
      metaphases II oocytes were retrieved in 10 patients and two embryos were formed and freshly&#xD;
      transferred followed by a healthy singleton delivery in 1 (1.25%) patient. They concluded&#xD;
      that the technique of ovarian biopsy/scratch without chemical activation could promote&#xD;
      follicle development in vivo, suggesting it could bring promising benefits for some women&#xD;
      with POI.&#xD;
&#xD;
      In patient with POI/DOR, activation of residual follicles is a promising option and further&#xD;
      studies are warranted. Previous studies included laparoscopic surgery which may lead to&#xD;
      possible surgical complications. Without using chemical agents and laparoscopic surgery, main&#xD;
      object of this study is mechanical follicle activation with trans-vaginal ovarian needle&#xD;
      puncture with 17 gauge oocyte pickup needle in IVF patients with DOR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of ≥14 mm follicle</measure>
    <time_frame>4 month after intervention as a response to ovarian stimulation</time_frame>
    <description>Number of ≥14 mm follicle on the trigger day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antral follicle count</measure>
    <time_frame>4 month after intervention on the second/third day of menstrual cycle</time_frame>
    <description>Antral follicle count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of collected oocytes</measure>
    <time_frame>4 month after intervention as a response to ovarian stimulation</time_frame>
    <description>Number of collected oocytes on the oocyte pick-up day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Activation of Primordial Follicles</condition>
  <arm_group>
    <arm_group_label>Control ovary</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Punctured ovary</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ovarian puncture</intervention_name>
    <description>One side ovary of each patient included in the study, will be punctured 10 times under trans-vaginal ultrasound guidance with 17 gauge ovarian pick up needle, 1 month before the scheduled IVF cycle. Control group will be the other side ovary for each patient. Number of ≥ 14 mm follicle and collected oocytes will be compared.</description>
    <arm_group_label>Punctured ovary</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with diminished ovarian reserve&#xD;
&#xD;
          -  &lt;3 oocytes collected in previous cycle (with anti-mullerian hormone &lt;0.5 ng/mL and/or&#xD;
             antral follicle count &lt;5)&#xD;
&#xD;
          -  Cycles stimulated with flexible antagonist protocol&#xD;
&#xD;
          -  Cycles triggered with recombinant hCG&#xD;
&#xD;
          -  Fresh transfer cycles&#xD;
&#xD;
          -  Patients with &lt;40 years of age&#xD;
&#xD;
          -  BMI &lt;30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preimplantation genetic testing&#xD;
&#xD;
          -  Azospermia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sezcan Mumusoğlu, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hacettepe University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sezcan Mumusoglu, Assoc. Prof.</last_name>
    <phone>+905326404673</phone>
    <email>sezcanmumusoglu@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hacettepe UniversityHacettepe University School of Medicine, Department of Ob/Gyn</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sezcan Mumusoglu, Assoc. Prof.</last_name>
      <phone>+905326404673</phone>
      <email>sezcanmumusoglu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gurkan Bozdag, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sezcan Mumusoglu, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esra Uyanık, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haldun Murat Erden, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010 Sep 11;376(9744):911-21. doi: 10.1016/S0140-6736(10)60355-8. Epub 2010 Aug 11. Review.</citation>
    <PMID>20708256</PMID>
  </reference>
  <reference>
    <citation>Torrealday S, Kodaman P, Pal L. Premature Ovarian Insufficiency - an update on recent advances in understanding and management. F1000Res. 2017 Nov 29;6:2069. doi: 10.12688/f1000research.11948.1. eCollection 2017. Review.</citation>
    <PMID>29225794</PMID>
  </reference>
  <reference>
    <citation>Ferraretti AP, Gianaroli L. The Bologna criteria for the definition of poor ovarian responders: is there a need for revision? Hum Reprod. 2014 Sep;29(9):1842-5. doi: 10.1093/humrep/deu139. Epub 2014 Jul 9.</citation>
    <PMID>25008235</PMID>
  </reference>
  <reference>
    <citation>Bachelot A, Nicolas C, Bidet M, Dulon J, Leban M, Golmard JL, Polak M, Touraine P. Long-term outcome of ovarian function in women with intermittent premature ovarian insufficiency. Clin Endocrinol (Oxf). 2017 Feb;86(2):223-228. doi: 10.1111/cen.13105. Epub 2016 Jun 14.</citation>
    <PMID>27177971</PMID>
  </reference>
  <reference>
    <citation>Chen X, Chen SL, Ye DS, Liu YD, He YX, Tian XL, Xu LJ, Tao T. Retrospective analysis of reproductive outcomes in women with primary ovarian insufficiency showing intermittent follicular development. Reprod Biomed Online. 2016 Apr;32(4):427-33. doi: 10.1016/j.rbmo.2015.12.011. Epub 2016 Jan 14.</citation>
    <PMID>26825246</PMID>
  </reference>
  <reference>
    <citation>Kawamura K, Kawamura N, Hsueh AJ. Activation of dormant follicles: a new treatment for premature ovarian failure? Curr Opin Obstet Gynecol. 2016 Jun;28(3):217-22. doi: 10.1097/GCO.0000000000000268. Review.</citation>
    <PMID>27022685</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Han T, Yan L, Jiao X, Qin Y, Chen ZJ. Resumption of Ovarian Function After Ovarian Biopsy/Scratch in Patients With Premature Ovarian Insufficiency. Reprod Sci. 2019 Feb;26(2):207-213. doi: 10.1177/1933719118818906. Epub 2018 Dec 12.</citation>
    <PMID>30541396</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 25, 2020</study_first_submitted>
  <study_first_submitted_qc>October 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hacettepe University</investigator_affiliation>
    <investigator_full_name>Sezcan Mumusoglu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Follicle Activation</keyword>
  <keyword>Premature Ovarian Insufficiency</keyword>
  <keyword>Diminished Ovarian Reserve</keyword>
  <keyword>Ovarian Puncture</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

